Tag: osé
Ose Immuno: the title benefits from a broker analysis – 06/17/2022 at 16:47
(CercleFinance.com) – The Ose Immunotherapeutics share gained almost 6% in Paris, benefiting from a positive analysis by Invest Securities which maintained its buy opinion on the share and its price…
Ose Immuno: the title benefits from a broker analysis
(CercleFinance.com) – The Ose Immunotherapeutics share gained almost 6% in Paris, benefiting from a positive analysis by Invest Securities which maintained its buy opinion on the share and its price…
Ose immuno: Six experts join the scientific council
Read also (CercleFinance.com) – OSE Immunotherapeutics announces the appointment of six leading international experts to its new Scientific Board to support the Company in its new phase of growth and…
OSE Immuno: six experts join the scientific council
(CercleFinance.com) – OSE Immunotherapeutics announces the appointment of six leading international experts to its new Scientific Board to support the Company in its new phase of growth and its scientific…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…
Presentations by OSE Immunotherapeutics at upcoming international congresses in London and Boston: ‘Immuno-Oncology Summit Europe’ and ‘Tumor Myeloid-Directed Therapies Summit’ – 05/11/2022 at 6:00 p.m.
Presentations on CLEC-1, a new myeloid checkpoint inhibitor target In cancer immunotherapy Nantes, France – May 11, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been…
Ose Immuno and Boehringer Ingelheim Announce First Patient Treated in Phase 1 Expansion Clinical Trial of BI 765063
By Claude Leguilloux Published on 05/03/2022 at 6:20 p.m. Photo credit © Reuters …
Ose immuno: A European patent for CLEC-1
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
OSE Immunotherapeutics: new European patent – 05/02/2022 at 08:46
(AOF) – OSE Immunotherapeutics has announced that the European Patent Office (EPO) has granted a new patent that enhances the protection of CLEC-1 (among CLR – C-type lectin receptors), its…
OSE Immuno: a European patent for CLEC-1
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…
OSE Immuno: a European patent for CLEC-1 – 05/02/2022 at 09:45
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…
Ose Immunotherapeutics: loss of sand but revenue up – 03/31/2022 at 08:58
(AOF) – In 2021, OSE Immunotherapeutics posted a net loss of 16.85 million euros compared to a loss of 16.555 million in 2020. The biotech’s current operating loss stood at…